Imunon, Inc.
IMNNDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
Epithelial Ovarian Cancer
ThermoDox
Hepatocellular Carcinoma
IMNN-101
SARS CoV 2 Infection
ThermoDox in combination with Microwave Hyperthermia (heat)
Breast Cancer
IMNN-001
Epithelial Ovarian Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) | Phase 3 | Epithelial Ovarian Cancer | - | - |
ThermoDox | Phase 3 | Hepatocellular Carcinoma | - | - |
IMNN-101 | Phase 2 | SARS CoV 2 Infection | - | - |
ThermoDox in combination with Microwave Hyperthermia (heat) | Phase 2 | Breast Cancer | - | - |
IMNN-001 | Phase 2 | Epithelial Ovarian Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Imunon, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Imunon, Inc.'s (IMNN) pipeline across Phase 3, Phase 2. Its lead program is IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Imunon, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Imunon, Inc. (IMNN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IMNN biotech catalysts?→
Add IMNN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Imunon, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.